1. Gerbes AL, Gülberg V, Holl J, Waggershauser T, Reiser M. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: Comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 1998; 28:683-688.
  2. Rössle M, Ochs A, Gülberg V, Siegerstetter V, Holl J, Deibert P, Olschewski M, Reiser M, Gerbes AL. A comparison of paracentesis and the transjugular intrahepatic portosystemic shunt for patients with refractory and recurrent ascites. N Engl J Med 2000; 342:1701-1707.
  3. Gerbes AL, Gülberg V, Bilzer M, Vogeser M. Evaluation of serum Cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002; 50:106-110
  4. Gerbes AL, Gülberg V, Gines P, Decaux G, Gross P, Gandjini H, Djian J. Therapy of hyponatremia in cirrhosis with an orally-active vasopressin receptor antagonist – a randomized double-blind multicenter trial. Gastroenterology 2003; 124:933-939.
  5. Salerno F, Gerbes AL, Gines P, Wong F, Arroyo V. Definition, diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. A consensus workshop of the international ascites club. Gut 2007; 56:1310-8.
  6. Benesic A, Leitl A, Gerbes AL. Monocyte-derivated hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver Injury. Gut 2016; 65:9 1555-1563.
  7. Markwardt D, Holdt L, Steib C, Benesic A, Bendtsen F, Bernardi M, Moreau R, Teupser D, Wendon J, Nevens F, Trebicka J, Garcia E, Pavesi M, Arroyo V, Gerbes AL. Plasma Cystatin C is a Predictor of Renal Dysfunction, Acute-on-Chronic Liver Failure, and Mortality in Patients with Acutely Decompensated Liver Cirrhosis. Hepatology 2017; 66:1232-1241.
  8. Gerbes AL, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut 2018; 67:380-388.
  9. Benesic A, Rotter I, Dragoi D, Weber S, Buchholtz M, Gerbes AL. Development and validation of a test to identify drugs that cause idiosyncratic drug-induced liver injury. Clin Gastro Hep 2018; 16(9):1488-1494.e5.
  10. Diana Dragoi, Andreas Benesic, Garwin Pichler, Nils A. Kulak, Harald S. Bartsch, Alexander L. Gerbes. Proteomics analysis of Monocyte-Derived Hepatocyte-Like Cells Identifies Integrin Beta 3 as a Specific Biomarker for Drug-Induced Liver Injury by Diclofenac. Frontiers in Pharmacology 2018; Jul 4;9:699, doi: 10.3389/fphar.2018.00699